Table of Contents
NEW YORK — Lamisil AT is introducing an innovative breakthrough in the category that provides fast symptom relief, helping to drive greater patient compliance. The new Jock Itch Cream is clinically proven to eliminate the fungus behind jock itch in just one week.
“We’re launching Lamisil AT Jock Itch Cream to make treating fungal infections simpler,” said Tamara Savitz, Senior Brand Manager at Karo Healthcare USA. “With just one application a day for one week, its treatment time is two times faster than the leading brand*, so people can experience fast symptom relief and move on.”
Karo Healthcare acquired Lamisil AT in 2023 with a mission to bring innovation to the antifungal category and leverage its strength in consumer health brands.
The prescription-strength formula is powered by Terbinafine Hydrochloride 1%, a trusted, highly effective antifungal ingredient to cure most jock itch in just one week. Lamisil AT targets and destroys tinea cruris fungus at its source while providing fast symptom relief against itching, burning, and redness.
Jock itch is a significant business for retailers, impacting an estimated 10% to 20% of the population, according to data from the National Library of Medicine. While men are three times more likely to be affected, women can also experience the same troublesome symptoms.
The self-care revolution, combined with social media advice from content creators, including dermatologists, is bringing men's health issues like jock itch to the forefront. The hashtag #menshealth has more than 427 million views, thousands of them concerning jock itch remedies.
Lamisil AT's commitment to consumer education and demand driving initiatives provides retailers an opportunity to attract shoppers and make their stores the category destination while driving category growth with effective and affordable choices. The 0.42-ounce cream retails for an MSRP of $17.99.
